Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Bioxytran Inc BIXT

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes... see more

OTCQB:BIXT - Post Discussion

Bioxytran Inc > Presenting on the Emerging Growth Conference 73 Day 2 on Jul
View:
Post by whytestocks on Jul 17, 2024 11:02am

Presenting on the Emerging Growth Conference 73 Day 2 on Jul

Just In: $BIXT Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register NowMIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 73 r d Emerging Growth Conference on July 17 & 18 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, w...BIXT - Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities